Most patients with nAMD can achieve a 12-week aflibercept dosing interval

Approximately 68% of patients with neovascular age-related macular degeneration (nAMD) included in a retrospective, comparative study were able to achieve a 12-week (q12) aflibercept dosing interval within the first 2 years of treatment, while having a similar visual acuity outcome and fewer total injections to patients unable to achieve q12 injection interval.

The electronic medical records of 2163 patients (2416 eyes) beginning anti-VEGF treatment who had received ≥7 aflibercept intravitreal injections were analyzed. During the first 2 years of treatment, 1674 (68%) eyes of 1537 patients had at least one q12 dosing interval. It took a median 1.76 years to the first q12 injection with a mean (±SD) of 11.8 (±6.0) injections.

Visual acuity (ETDRS letters) of the eyes without q12 injection was 57.9 ± 14 at baseline, 61.4 ± 18.1 at 12 months, and 61.2 ± 20.1 at 2 years. Visual acuity of the eyes with a q12 injection was 56.7 ± 14.8, 63.0 ± 15.9, and 61.1 ± 17.8, respectively.

Reference
Fu DJ, Hanumunthadu D, Keenan TDLet al. Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre. Eye (Lond). 2022 Sep 9. doi: 10.1038/s41433-022-02220-1. Epub ahead of print. PMID: 36085360.